health risks of semaglutide Who Should Consider GLP-1? Semaglutide GLP-1 is generally recommended for individuals with type 2 diabetes who have not achieved adequate blood sugar control with other medications such as metformin, or for Unleashing the Power of Semaglutide:

In 2024,the FDA also approved Wegovy to reduce the risk of cardiovascular-related death, heart attack, and stroke in adults with cardiovascular disease

Active medication supply was constructed using dispense dates and days supply

This medication belongs to a class of drugs called GLP-1 receptor agonists

What is the Procedure

New England Journal of Medicine: GLP-1 Receptor Agonists , a comprehensive review of GLP-1 receptor agonist pharmacology, clinical outcomes, and emerging therapeutic applications from one of the most respected medical journals in the world

Rebound Risks : Weight regain common post-semaglutide due to increased appetite and fat production